Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma - Summary - MDSpire
Advertisement
Study explores adding a low-dose, daily oral chemotherapy for patients with melanoma
UCI Health medical oncologist Poorva Vaidya, MD is currently offering a new clinical trial sponsored by the UC Irvine Anti-Cancer Challenge, and lead by Warren Chow, MD, aimed at tackling a persistent challenge in melanoma care if patients fail first-line immunotherapy.
To investigate the addition of low-dose, daily oral chemotherapy (cyclophosphamide) to standard immunotherapy for melanoma patients who have progressed after first-line treatment.
Approach:
Clinical Trial: The trial is sponsored by the UC Irvine Anti-Cancer Challenge and led by Warren Chow, MD.
Key Findings:
The study aims to address the challenge of resistance to immune checkpoint inhibitors in melanoma treatment.
Cyclophosphamide is used in a novel, continuous regimen to potentially re-engage the immune system.
Interpretation:
The trial is in early stages and is open for further patient accrual.
Limitations:
The trial is still in its early stages, and results are not yet available.
Conclusion:
The research team aims to gather meaningful insights by ASCO 2027.
